BridgeMD
New treatment option for Parkinson Disease
Official title Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
ClinicalTrials.gov ID: NCT07324330
What this study is testing
- What it's testing
- α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases. In addition to progressive motor deterioration, cognitive decline is a key element of the non-motor symptom complex of these diseases.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 80. Healthy volunteers may be eligible.
You may be able to join if
- iRBD:
- Age: 50-80 years
- Polysomnographically confirmed diagnosis of iRBD
- Maximum of 120 minutes of sports/outdoor activities per day
- Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase
You likely can't join if
- iRBD:
- Relevant cardiovascular diseases
- Problems with dexterity or cognitive impairments that make it difficult to use a smartphone
- Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study
- Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible) Healthy controls:
- Relevant cardiovascular diseases
See the full eligibility criteria
- iRBD:
- Age: 50-80 years
- Polysomnographically confirmed diagnosis of iRBD
- Maximum of 120 minutes of sports/outdoor activities per day
- Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase
- Basic smartphone skills
- Sufficient knowledge of German (native language, C1 or C2)
- Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)
- Consent to be informed of any additional findings Healthy controls:
- Age: 50-80 years
- Maximum of 120 minutes of sports/outdoor activities per day
- Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase
- Basic smartphone skills
- Sufficient knowledge of German (native language, C1 or C2)
- Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)
- Consent to be informed of any additional findings
- iRBD:
- Relevant cardiovascular diseases
- Problems with dexterity or cognitive impairments that make it difficult to use a smartphone
- Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study
- Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible) Healthy controls:
- Relevant cardiovascular diseases
- Problems with dexterity or cognitive impairments that make it difficult to use a smartphone
- Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study
- Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)
- clinically diagnosed iRBD
The study team makes the final eligibility decision.
Where it's taking place
- Bonn, North Rhine West-Falia, Germany
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 80 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bonn, North Rhine West-Falia, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.